Delving into the Latest Updates on RSVpreF with Synapse

Overview

Basic Info

Drug Type

Prophylactic vaccine

Synonyms

recombinant respiratory syncytial virus pre-fusion F protein, water for injections(Pfizer), Respiratory Syncytial Virus Vaccine, PF 06928316

+ [4]

Target

RSV F protein

Action

modulators

Mechanism

Respiratory syncytial virus F protein modulators(Respiratory syncytial virus F protein modulators)

Therapeutic Areas

Infectious DiseasesRespiratory Diseases

Active Indication

Pneumonia due to respiratory syncytial virusRespiratory Syncytial Virus InfectionsLower Respiratory Tract Infections

Inactive Indication-

Originator Organization

Pfizer Inc.

Active Organization

Pfizer Europe MA EEIGPfizer Canada ULC

Pfizer Inc.

+ [1]

Inactive Organization-

License Organization-

Drug Highest PhaseApproved

First Approval Date

Canada (04 Jan 2023),

Lower Respiratory Tract Infections

RegulationPriority Review (United States), Breakthrough Therapy (United States), Fast Track (United States)

Login to view timeline

The overall objective of Tarsila Study is to estimate the real-world vaccine effectiveness of maternal RSVpreF immunization during pregnancy in Brazil against medically attended (inpatient and outpatient) respiratory syncytial virus-associated acute respiratory illness in infants. To achieve this, two multicenter, prospective, test-negative case-control studies will be conducted among infants with ARI: the TARSILA Inpatient Study, evaluating hospitalized infants and the TARSILA Outpatient Study, evaluating infants managed in outpatient settings.

Start Date30 Apr 2026

Sponsor / Collaborator

Innovea Medical Ltd.

[+1]

NCT07235397

/ Not yet recruitingNot Applicable

Evaluating the Benefits Of RSV MaternaL vAccination Using a Scottish National Dataset.

This study will use a retrospective cohort design and will be conducted within routinely collected national healthcare and statutory demographic datasets held by PHS and National Records of Scotland (NRS). As such, there will be no active enrollment of study participants, no direct contact with study participants, no collection of any primary data outside of the standard of care (SOC), and no requirement for informed consent.
This study design was chosen due to several advantages, over other possible designs, including the ability to evaluate incidence of study outcomes in exposed and unexposed infants, ability to follow infants longitudinally to evaluate study outcomes through 12 months of age, and ability to evaluate all-cause outcomes.
Study endpoints, including RSV-associated LRTD hospitalization and RSV-associated hospitalization, among infants born to ABRYSVO-vaccinated mothers (exposed group) will be compared with those among infants born to ABRYSVO-unvaccinated mothers (comparison group) initially from birth through 6 months of age, with later analysis from birth through 12 months as the infants reach this age threshold and their data become available.

Start Date01 Apr 2026

Sponsor / Collaborator

Pfizer Inc.

NCT07279298

/ Not yet recruitingNot ApplicableIIT

Effectiveness of Immunization in Preventing Severe Acute Respiratory Infection Associated With Respiratory Syncytial Virus-RSV- in Infants Under 6 Months of Age in Bogotá: a Case-control Study With a Negative Test Design

This study aims to evaluate the real-world effectiveness of two preventive immunization strategies against Respiratory Syncytial Virus (RSV)-associated severe acute respiratory infection in infants less than six months of age in Bogotá, Colombia. The strategies include maternal vaccination with RSVpreF administered between 28 and 36 weeks of gestation and neonatal immunization with nirsevimab for infants born to mothers who did not receive RSVpreF during pregnancy. Using a test-negative case-control design embedded in the city's sentinel surveillance system, infants hospitalized for severe respiratory infection will be systematically tested for RSV. Comparative vaccine effectiveness will be estimated to determine the impact of maternal RSV vaccination and neonatal monoclonal antibody immunization on RSV-associated hospitalizations, intensive care admissions, and mortality. The study will generate real-world evidence to inform local and regional public health decisions and guide the implementation of cost-effective hybrid immunization strategies against RSV in middle-income settings.

Start Date01 Feb 2026

Sponsor / Collaborator-

100 Clinical Results associated with RSVpreF

Login to view more data

100 Translational Medicine associated with RSVpreF

Login to view more data

100 Patents (Medical) associated with RSVpreF

Login to view more data

415

Literatures (Medical) associated with RSVpreF

31 Dec 2026·Human Vaccines & Immunotherapeutics

Parental acceptability of new RSV preventive therapies for infants: A cross-sectional survey in Canada

Article

Author: Moss, Stephana Julia ; Lee, Janet S W ; Vadlamudi, Nirma Khatri ; Castillo, Eliana ; MacDonald, Shannon E ; Dubé, Ève ; Bolotin, Shelly ; Halperin, Scott A ; MacDonald, Jade ; Fitzpatrick, Tiffany ; Greyson, Devon ; Manca, Terra ; Buchan, Sarah A ; Comeau, Jeannette L ; Papenburg, Jesse ; Parsons Leigh, Jeanna ; Blanchard, Wade ; Halperin, Donna ; Langley, Joanne M ; Brousseau, Nicholas ; Brundin-Mather, Rebecca

Two new RSV immunization products exist for infants: a prenatal vaccine (RSVpreF) and a long-acting monoclonal antibody for infants (nirsevimab). While both showed promise in clinical trials, implementation has varied across jurisdictions. Before rollout in Canada, we conducted an anonymized, online survey with a nationally representative sample of 1,015 expectant and recent birth parents. The primary outcome was product acceptability (disagree, undecided, agree). Odds ratios (ORs) and 95% confidence intervals (CIs) identified factors associated with agreement or indecision versus disagreement. Approximately 49% (n = 499) were expecting; 51% (n = 516) had a baby in the past year. Overall, 72% (n = 727) agreed to receive a product: 61% (n = 624) for RSVpreF and 60% (n = 608) for nirsevimab. RSVpreF agreement was higher among older parents (e.g., OR = 3.64; 95% CI, 1.99-6.67 for age 25-34 versus 18-24 years), those with a university degree (OR = 3.65; 95% CI, 2.01-6.64 versus high school), higher income (OR = 2.31; 95% CI, 1.01-5.28 for ≥$150k versus <$40k), or receipt/intention for Tdap (OR = 3.76; 95% CI, 2.37-5.96 versus no receipt/intention) or influenza (OR = 2.04; 95% CI, 1.29-3.21) vaccines. Agreement was higher among parents of children without a high-risk medical condition compared to those with (OR = 2.32; 95% CI, 1.44-3.72). Similar trends were observed for nirsevimab, with lower agreement also noted among those who self-researched antibodies (OR = 0.51; 95% CI, 0.30-0.88 versus not). As most respondents rated product safety (76%), effectiveness (71%), and disease severity risk (70%) as important in decision-making, providing clear information on these, alongside communications targeted to subgroups with lower agreement, may optimize uptake as programs rollout.

31 Dec 2026·Human Vaccines & Immunotherapeutics

Mucosal immunization with an adenoviral vector expressing a prefusogenic F protein protects the upper and lower respiratory tracts of cotton rats against live respiratory syncytial virus challenge

Article

Author: Wang, Qiyao ; Wang, Shen ; Bao, Jianwei ; Lu, Shuangshuang ; Wu, Ke ; Xu, Long ; Mu, Ting ; Zhang, Ying ; Xie, Liang ; Klein, Michel ; Ma, Tao ; Sun, Bing

Respiratory syncytial virus (RSV) is a major cause of severe respiratory disease in infants, young children, and the elderly. Current licensed prefusogenic F-based RSV vaccines induce systemic immune responses through intramuscular injection. However, mucosal immunization will be required to elicit local sterilizing immunity to prevent virus replication in the nasopharynx and the lungs as well as virus shedding and transmission. Adenovirus vectors are a promising platform to develop RSV vaccines, but further evaluation of mucosal adenovirus-based prefusion F (preF) vaccines is still needed. In this study, we constructed a recombinant chimpanzee adenovirus serotype 68 vector expressing a second-generation disulfide-stabilized (DS2)trimeric preF protein (ChAd68-PreF). In mice, intranasal immunization with ChAd68-PreF induced dose-dependent increase in RSV-specific secretory IgA (sIgA) in the lower respiratory tract, demonstrating its capacity to elict mucosal immunity. Subsequently, in cotton rats, intratracheal instillation of ChAd68-PreF induced high cross-neutralizing antibody titers against RSV A and RSV B. After RSV A2 challenge, ChAd68-PreF vaccinated animals showed no detectable viral replication in the nose nor in the lungs. Moreover, ChAd68-PreF vaccination did not lead to enhanced respiratory disease (ERD) in cotton rats. These results demonstrate that mucosal delivery of ChAd68-PreF confers potent protective immunity against RSV with good safety profile, warranting further clinical development as a mucosa-targeting RSV vaccine for vulnerable populations.

03 Mar 2026·JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Nirsevimab vs RSVpreF Vaccine for Respiratory Syncytial Virus–Related Hospitalization in Newborns

Article

Author: Gabet, Amélie ; Bertrand, Marion ; Kolla, Epiphane ; Zureik, Mahmoud ; Olié, Valérie ; Jabagi, Marie-Joelle

Importance:

Respiratory syncytial virus (RSV) is a leading cause of hospitalization in infants. The comparative effectiveness of 2 recently introduced preventive strategies (infant immunization through placental antibody transfer after maternal vaccination with the RSV prefusion F protein [RSVpreF] vaccine and passive infant immunization with nirsevimab) remains unknown.

Objective:

To compare the associations of maternal vaccination with the RSVpreF vaccine vs passive infant immunization with nirsevimab for the prevention of RSV-related hospitalization.

Design, Setting, and Participants:

This population-based cohort study used data from the French National Health Data System. Maternal vaccination with the RSVpreF vaccine occurred during 32 to 36 weeks’ gestation among infants born in mainland France between September 1 and December 31, 2024. Passive infant immunization with nirsevimab occurred prior to hospital discharge. Infants were matched 1:1 by maternity ward discharge date, sex, gestational age, and region. Follow-up ended at the time of RSV hospitalization or death or on February 28, 2025.

Exposures:

Maternal immunization with the RSVpreF vaccine and passive infant immunization with nirsevimab.

Main Outcomes and Measures:

The primary outcome was hospitalization for RSV-associated lower respiratory tract infection. The secondary outcomes included admission to the pediatric intensive care unit (PICU), admission to high-dependency unit, ventilator support, and oxygen therapy. The hazard ratios (HRs) were estimated using conditional Cox proportional hazards models with inverse probability of treatment weighting.

Results:

A total of 42 560 infants (mean age, 3.7 [SD, 1.4] days; 51.7% male) were included in the study (21 280 per group) with a median follow-up of 84 days (IQR, 70-99 days). Of the 481 hospitalizations for RSV-associated lower respiratory tract infection, 212 (44.1%) occurred in the nirsevimab group vs 269 (55.9%) in the RSVpreF vaccine group (between-group difference, −11.8% [95% CI, −18.1% to −5.5%]). Compared with the RSVpreF vaccine, passive infant immunization with nirsevimab was associated with a lower risk of hospitalization for RSV-associated lower respiratory tract infection (adjusted HR, 0.74 [95% CI, 0.61 to 0.88]). Compared with the RSVpreF vaccine, passive infant immunization with nirsevimab was associated with a lower risk of severe outcomes, including PICU admission (adjusted HR, 0.58 [95% CI, 0.42 to 0.80]), requiring ventilator support (adjusted HR, 0.57 [95% CI, 0.40 to 0.81]), or requiring oxygen therapy (adjusted HR, 0.56 [95% CI, 0.38 to 0.81]). The results were consistent across subgroups and in the sensitivity analyses.

Conclusions and Relevance:

Compared with maternal vaccination with the RSVpreF vaccine, passive infant immunization with nirsevimab was associated with lower risks of RSV-related hospitalization and severe outcomes. These findings reflect the first RSV season with use of these immunization strategies in mainland France; their use should be reevaluated in future studies.

401

News (Medical) associated with RSVpreF

16 Mar 2026

·allsci.com

FDA approves GSK’s RSV vaccine Arexvy for adults aged 18–49

The US FDA has approved an expanded age indication for Arexvy (respiratory syncytial virus vaccine, adjuvanted), GSK’s recombinant protein-based RSV vaccine, extending its use to adults aged 18 to 49 years at increased risk for lower respiratory tract disease caused by RSV. The decision makes Arexvy the third RSV vaccine to receive US FDA approval for at-risk adults under 50, following earlier label expansions for Pfizer’s Abrysvo in October 2024 and Moderna’s mRESVIA in 2025. Arexvy was previously approved in the US for adults aged 60 and older, and for those aged 50 to 59 at increased risk. An estimated 21 million US adults under 50 have at least one risk factor for severe RSV infection, the company said. The expanded indication covers adults aged 18 to 49 with chronic conditions that elevate RSV risk, including cardiopulmonary, kidney, and metabolic diseases such as diabetes and obesity. The vaccine is not approved for use in pregnant individuals. Arexvy contains a recombinant RSV glycoprotein F stabilized in the prefusion conformation (RSVPreF3), combined with GSK’s proprietary AS01E adjuvant system. It is administered as a single dose. The vaccine is now approved for adults 18 and older in the European Economic Area and across more than 60 countries for various adult age groups. The FDA’s decision was supported by data from a Phase IIIb open-label trial (NCT06389487) enrolling 1,458 participants across 52 sites in six countries. The study evaluated the immune response in 426 at-risk adults aged 18 to 49 compared with 429 adults aged 60 and above after a single dose. Primary endpoints were RSV-A and RSV-B neutralization titres at one month post-vaccination. The trial met its non-inferiority endpoints, demonstrating that the immune response in the younger at-risk cohort was non-inferior to that observed in older adults. Vaccine efficacy against RSV-associated lower respiratory tract disease had been established in the earlier Phase III trial (NCT04886596), which enrolled over 26,000 adults aged 60 and above. The safety profile in the expanded population was consistent with the broader Phase III programme, with injection site pain, fatigue, myalgia, headache, and arthralgia the most commonly reported adverse events. The approval places Arexvy alongside two other vaccines now available for younger at-risk adults, forming a competitive landscape that includes protein subunit, mRNA, and bivalent approaches. Pfizer’s Abrysvo, a non-adjuvanted bivalent prefusion F protein vaccine, received its 18-to-59 expansion in October 2024. Moderna’s mRESVIA, the only mRNA-based RSV vaccine, also gained approval for adults 18 to 59 at increased risk in 2025. All three approvals in younger adults relied on immunobridging strategies rather than direct efficacy endpoints in the target population. RSV accounts for approximately 17,000 hospitalisations, 277,000 emergency department visits, and nearly two million outpatient visits annually among US adults aged 18 to 49, with most hospitalisations occurring in those with chronic medical conditions. Prior to these vaccine approvals, no specific prophylactic or therapeutic intervention existed for RSV prevention in this age group. GSK continues to pursue regulatory submissions globally, and the company is conducting additional studies, including a Phase III trial in Chinese adults aged 18 to 59 at increased risk. Your email address will not be published. Required fields are marked * Comment * Name * Email * Website

Phase 3Drug ApprovalVaccineClinical ResultmRNA

16 Mar 2026

·www.pharmaceutical-technology.com

GSK’s RSV jab secures FDA label expansion to larger adult population

Arexvy will now join Abrysvo and mRESVIA on the high-risk 18-49 market. Credit: MargJohnsonVA / Shutterstock.com. GSK has secured a label expansion for its respiratory syncytial virus (RSV) vaccine, Arexvy, from the US Food and Drug Administration (FDA) – broadening the jab’s commercial reach on American soil. Through this new approval, Arexvy will be available as a preventative measure to non-pregnant adults aged between 18 and 49 years of age, provided they are at increased risk of developing RSV-associated lower respiratory tract disease (LRTD). The FDA based its decision on data from a global Phase IIIb trial (NCT06389487), which confirmed Arexvy’s non-inferiority in immune response across the 18 to 49 age range compared with that seen in patients over 60 in a separate Phase III study (NCT04886596). Arexvy made its market debut in 2023 after becoming the first RSV vaccine to secure regulatory approval in the US – though the shot was originally indicated for the 60+ age demographic only. GSK later secured a label expansion for Arexvy into the 50-59 age category. Since its original approval, Arexvy has encountered competition from both Moderna and Pfizer, as the two pharma companies have both secured regulatory approval for their RSV vaccines, mRESVIA and Abrysvo, across the entire high-risk adult market. According to analysts at GlobalData, parent company of Pharmaceutical Technology , sales of all three vaccines will experience a downturn in the next few years due to shifting attitudes towards vaccines across the US. However, analysts expect Abrysvo to absorb the largest share of the RSV market in 2030 out of the three by bringing in $1bn for Pfizer. GlobalData predicts that Arexvy and mResvia will generate $938m and $502m in sales, respectively, in 2030. GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate? Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis. By GlobalData Learn more about Strategic Intelligence GSK plans to expand Arexvy’s commercial footprint by submitting further applications for the vaccine to regulators across multiple geographies. US vaccine policy evolves Arexvy’s expanded label comes as the US government looks to alter vaccine policy across the country. In January 2023, the Centers for Disease Control (CDC) updated the routine childhood immunisation schedule , shrinking the recommended list down from 18 vaccines to 11. The RSV vaccine was one of the seven jabs the CDC removed from this schedule. Now, the US health secretary, Robert F Kennedy Jr (RFK Jr), has plans to further reduce this list as he plans to remove seven of the 11 remaining shots on the routine list. This shifting perception can also be observed in the FDA, as the agency’s Center for Biologics Evaluation and Research (CBER) previously declined to review Moderna’s seasonal influenza vaccine, mRNA-1010, due to concerns around the supporting trial’s design. The FDA later pivoted on this take, agreeing to review the drug after Moderna appealed the decision. The FDA’s approval of Arexvy comes soon after FDA commissioner Marty Makary announced that Vinay Prasad would be leaving his post at the helm of CBER for the second time.

Phase 3VaccineDrug ApprovalClinical ResultmRNA

13 Mar 2026

·www.fiercepharma.com

GSK catches up to Pfizer, Moderna with FDA expansion for Arexvy

With an FDA expansion for GSK’s RSV vaccine, Arexvy, for at-risk adults ages 18 to 49, the British company has caught up with Pfizer and Moderna, which scored nods for the age group in 2024 and 2025, respectively. GSK has secured an FDA expansion for its respiratory syncytial virus (RSV) vaccine, Arexvy, for adults ages 18 to 49 who are at increased risk of lower respiratory tract disease caused by the virus. The green light puts GSK on a level playing field with Pfizer and Moderna, which secured endorsements for their RSV shots in 2025 and 2024, respectively. All three of the shots were originally approved for the prevention of RSV in adults 60 and older. In June 2024, GSK gained FDA clearance for at-risk adults age 50 and older, with Pfizer achieving its larger at-risk age expansion four months later.“This age expansion can help address a significant medical need for adults in the United States at higher risk of severe RSV disease due to certain underlying conditions, and help ease pressure on the healthcare system,” Sanjay Gurunathan, M.D., GSK’s vaccines R&D chief, said in a release. Two months ago, Europe signed off on Arexvy’s use for all adults—regardless of their health status—in the same age group.Roughly 17,000 people ages 18 to 49 are hospitalized for RSV in the U.S. each year, GSK said, with most of those affected having chronic medical conditions that place them at risk for severe RSV.The new GSK endorsement comes amid a pressurized vaccine environment in the U.S. In December, the Centers for Disease Control and Prevention (CDC) upended the immunization schedule for children in the U.S., chopping six shots that were previously recommended. Additionally, immunization against RSV—which is the top cause for infant hospitalizations in the U.S., according to the CDC—is now limited to those at high risk and children whose mothers have not been vaccinated.In Arexvy’s first year on the market in 2023, GSK reported worldwide sales of 1.2 billion pounds sterling ($1.49 billion), followed by a decline to 593 million pounds ($757 million) in 2024 and 590 million pounds ($777 million) last year. Meanwhile, sales of Pfizer’s Abrysvo increased from $755 million in 2024 to $1.03 billion last year.

Drug ApprovalVaccine

100 Deals associated with RSVpreF

Login to view more data

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Pneumonia due to respiratory syncytial virus	European Union	Pfizer Europe MA EEIG	23 Aug 2023
Pneumonia due to respiratory syncytial virus	Iceland	Pfizer Europe MA EEIG	23 Aug 2023
Pneumonia due to respiratory syncytial virus	Liechtenstein	Pfizer Europe MA EEIG	23 Aug 2023
Pneumonia due to respiratory syncytial virus	Norway	Pfizer Europe MA EEIG	23 Aug 2023
Respiratory Syncytial Virus Infections	United States	Pfizer Inc.	31 May 2023
Lower Respiratory Tract Infections	Canada	Pfizer Canada ULC	04 Jan 2023

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Respiratory Tract Infections	Phase 3	United States	Pfizer Inc.	17 Jun 2020
Respiratory Tract Infections	Phase 3	Japan	Pfizer Inc.	17 Jun 2020
Respiratory Tract Infections	Phase 3	Argentina	Pfizer Inc.	17 Jun 2020
Respiratory Tract Infections	Phase 3	Australia	Pfizer Inc.	17 Jun 2020
Respiratory Tract Infections	Phase 3	Brazil	Pfizer Inc.	17 Jun 2020
Respiratory Tract Infections	Phase 3	Canada	Pfizer Inc.	17 Jun 2020
Respiratory Tract Infections	Phase 3	Chile	Pfizer Inc.	17 Jun 2020
Respiratory Tract Infections	Phase 3	Denmark	Pfizer Inc.	17 Jun 2020
Respiratory Tract Infections	Phase 3	Finland	Pfizer Inc.	17 Jun 2020
Respiratory Tract Infections	Phase 3	Gambia	Pfizer Inc.	17 Jun 2020

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT06593587 (CTgov)	Phase 3	Respiratory Syncytial Virus Infections	378	Placebo	hjweavoycg = ffgybudvwx lyjayjjbzc (cutyywoibu, jyphxtyikv - jnrrregxwh) View more	-	09 Feb 2026
NCT06473519 (Amélie, CTgov)	Phase 3	Respiratory Syncytial Virus Infections	453	RSVpreF (RSVpreF (With Preservative, MDV))	ysxabvvhvq(alicgbdehh) = fypotcqhls vkzztqrbqx (caovvpouut, dkgzbyqagi - ctqeitebsp) View more	-	25 Sep 2025
				RSVpreF (RSVpreF (Without Preservative, SDV))	ysxabvvhvq(alicgbdehh) = txdmcluxld vkzztqrbqx (caovvpouut, bexfupewwk - zzbjvkmkai) View more
NCT05842967 (MONET, CTgov)	Phase 3	Respiratory Syncytial Virus Infections	885	SSA+RSVpreF (SSA: RSVpreF)	egvtmomhal = mlcfspogkr odgadgtvto (ghgrswotdh, kkpmryzliy - wqagqizxtb) View more	-	08 Aug 2025
				SSA (SSA: Placebo)	egvtmomhal = ynnkbxrnsy odgadgtvto (ghgrswotdh, cfwquarvyj - mddzoxyckh) View more
NCT04424316 (MATISSE, CTgov)	Phase 3	Respiratory Tract Infections	14,727	RSVpreF (Infant Participants: RSVpreF)	rsojdwfnso = jpkrjphjqq qysytrjjpj (sgdpfsexyf, fjkujadqld - hruititfpm) View more	-	11 Feb 2025
				placebo+RSVpreF (Infant Participants: Placebo)	rsojdwfnso = hrhrltpqju qysytrjjpj (sgdpfsexyf, dqgoyizhqz - aymgebbbkg) View more
NCT05035212 (2021-003693-31, Pubmed \| Clin Infect Dis)	Phase 3	-	-	Bivalent RSV Prefusion F (RSVpreF) Vaccine (RSVpreF 120-µg)	arqnsnwani(pxegkeicxx) = gctoexweij ghnddipvqk (tqtdpnftlv )	Positive	10 Feb 2025
				Bivalent RSV Prefusion F (RSVpreF) Vaccine (Placebo)	arqnsnwani(pxegkeicxx) = xdxftvjvcc ghnddipvqk (tqtdpnftlv )
NCT04424316 (MATISSE, Pubmed \| Obstet Gynecol)	Phase 3	Obstetric Labor, Premature	-	Bivalent Respiratory Syncytial Virus Prefusion F Protein Vaccine (RSVpreF)	zkdaywruuf(oztrjsvffk) = no clinically significant increase in adverse events of special interest, including preterm birth, low birth weight, or neonatal hospitalization, was observed among pregnant people in the overall analysis tpkznybeuy (nrdtkqcgaz ) View more	Positive	02 Jan 2025
				Bivalent Respiratory Syncytial Virus Prefusion F Protein Vaccine (Placebo)
NCT05842967 (MONeT, PipelineReview) Manual	Phase 3	Respiratory Syncytial Virus Infections	203	ABRYSVO	qrdpwzufry(sbrndpuqns) = ABRYSVO was well-tolerated during the trial, showing a safety profile consistent with findings from other studies of the vaccine. urcslctkox (ugzlbxddnp ) View more	Positive	12 Aug 2024
NCT04785612 (Phase 2a study, CTgov)	Phase 2	Respiratory Syncytial Virus Infections	70	RSVPreF (RSVPreF)	vdcrmiwtst(twgnbyjsze) = wlqcxnswfu jvffiqplno (qyzcconmjm, rthrniyfad - dekcgvfnxw) View more	-	07 Aug 2024
				Placebo (Placebo)	vdcrmiwtst(twgnbyjsze) = jgqajfiqwt jvffiqplno (qyzcconmjm, uaoemwerir - cvrdqwlzdq) View more
NCT04424316 (MATISSE, Pubmed)	Phase 3	Respiratory Syncytial Virus Infections	-	RSVpreF vaccine	kccmrtvqud(mffycggrib) = djhasoqsra jsewqqjhrf (phqeoslyop ) View more	Positive	08 Jun 2024
				bivalent RSVpreF maternal vaccination (Placebo)	kccmrtvqud(mffycggrib) = xknwkansrm jsewqqjhrf (phqeoslyop ) View more
NCT05842967 (MONeT, Corporate Publications) Manual	Phase 3	Pulmonary Disease, Chronic Obstructive \| Asthma \| Diabetes Mellitus ... View more	-	ABRYSVO	mougbycdyb(xonxwxtarz) = Participants demonstrated RSV-A and RSV-B subgroup neutralizing responses non-inferior to the response seen in the Phase 3 (NCT05035212) RENOIR study of ABRYSVO in more than 34,000 adults aged 60 or older where vaccine efficacy was previously demonstrated. eisyonalte (ejotqbjejr ) Met View more	Positive	09 Apr 2024